Pages that link to "Q35905947"

The following pages link to Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. (Q35905947):

Displaying 50 items.

• The causes and consequences of HIV evolution (Q22251040) (← links)
• Identification of an active reverse transcriptase enzyme encoded by a human endogenous HERV-K retrovirus (Q24517809) (← links)
• Role of the DIS hairpin in replication of human immunodeficiency virus type 1 (Q24680551) (← links)
• Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with beta-branched amino acids (Q24682078) (← links)
• Aggressive HIV-1? (Q24801219) (← links)
• Structural basis for activation of α-boranophosphate nucleotide analogues targeting drug-resistant reverse transcriptase (Q27625384) (← links)
• Mechanistic differences in RNA-dependent DNA polymerization and fidelity between murine leukemia virus and HIV-1 reverse transcriptases (Q28302073) (← links)
• A new point mutation (P157S) in the reverse transcriptase of human immunodeficiency virus type 1 confers low-level resistance to (-)-beta-2',3'-dideoxy-3'-thiacytidine (Q28343476) (← links)
• Selection and characterization of human immunodeficiency virus type 1 variants resistant to the (+) and (-) enantiomers of 2'-deoxy-3'-oxa-4'-thio-5-fluorocytidine (Q28344137) (← links)
• 3'-Azido-3'-deoxythymidine (AZT) mediates cross-resistance to nucleoside analogs in the case of AZT-resistant human immunodeficiency virus type 1 variants. (Q28379497) (← links)
• Optimal timing and duration of induction therapy for HIV-1 infection (Q28469250) (← links)
• Dynamics of HIV-1 quasispecies during antiviral treatment dissected using ultra-deep pyrosequencing (Q28474783) (← links)
• Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: a bayesian analysis (Q28478121) (← links)
• HIV-1 Env C2-V4 diversification in a slow-progressor infant reveals a flat but rugged fitness landscape (Q28487168) (← links)
• High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen (Q28538692) (← links)
• A second-site mutation that restores replication of a Tat-defective human immunodeficiency virus (Q30321811) (← links)
• The influence of charge clustering on the anti-HIV-1 activity and in vivo distribution of negatively charged albumins. (Q30330303) (← links)
• Comparative biochemical analysis of recombinant reverse transcriptase enzymes of HIV-1 subtype B and subtype C (Q30394627) (← links)
• Duck hepatitis B virus polymerase gene mutants associated with resistance to lamivudine have a decreased replication capacity in vitro and in vivo (Q32043207) (← links)
• Adaptation of HIV-1 depends on the host-cell environment (Q33277177) (← links)
• Effective treatment of SIVcpz-induced immunodeficiency in a captive western chimpanzee (Q33442370) (← links)
• Managing resistance to anti-HIV drugs: an important consideration for effective disease management. (Q33588535) (← links)
• Mutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration (Q33603586) (← links)
• Drastic fitness loss in human immunodeficiency virus type 1 upon serial bottleneck events. (Q33643192) (← links)
• A novel assay allows genotyping of the latent reservoir for human immunodeficiency virus type 1 in the resting CD4+ T cells of viremic patients (Q33724247) (← links)
• Increased multinucleoside drug resistance and decreased replicative capacity of a human immunodeficiency virus type 1 variant with an 8-amino-Acid insert in the reverse transcriptase (Q33737755) (← links)
• Mutations in HIV-1 reverse transcriptase affect the errors made in a single cycle of viral replication (Q33743954) (← links)
• HIV-1 Transmission, Replication Fitness and Disease Progression (Q33758570) (← links)
• A novel point mutation at position 156 of reverse transcriptase from feline immunodeficiency virus confers resistance to the combination of (-)-beta-2',3'-dideoxy-3'-thiacytidine and 3'-azido-3'-deoxythymidine (Q33782477) (← links)
• Therapy of chronic hepatitis B virus infection: inhibition of the viral polymerase and other antiviral strategies (Q33788626) (← links)
• The P236L delavirdine-resistant human immunodeficiency virus type 1 mutant is replication defective and demonstrates alterations in both RNA 5'-end- and DNA 3'-end-directed RNase H activities (Q33815628) (← links)
• Decreased processivity of human immunodeficiency virus type 1 reverse transcriptase (RT) containing didanosine-selected mutation Leu74Val: a comparative analysis of RT variants Leu74Val and lamivudine-selected Met184Val. (Q33820365) (← links)
• Relative replication fitness of a high-level 3'-azido-3'-deoxythymidine-resistant variant of human immunodeficiency virus type 1 possessing an amino acid deletion at codon 67 and a novel substitution (Thr-->Gly) at codon 69. (Q33826453) (← links)
• Strict control of human immunodeficiency virus type 1 replication by a genetic switch: Tet for Tat. (Q33835795) (← links)
• Individual contributions of mutant protease and reverse transcriptase to viral infectivity, replication, and protein maturation of antiretroviral drug-resistant human immunodeficiency virus type 1. (Q33838311) (← links)
• Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy. (Q33843040) (← links)
• YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: A study by in vitro full-length viral DNA transfection (Q33853661) (← links)
• Mutants of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors demonstrate altered rates of RNase H cleavage that correlate with HIV-1 replication fitness in cell culture (Q33873983) (← links)
• Genotypic testing for human immunodeficiency virus type 1 drug resistance (Q33906239) (← links)
• HIV drug resistance and viral fitness. (Q34050677) (← links)
• Effects of the W153L substitution in HIV reverse transcriptase on viral replication and drug resistance to multiple categories of reverse transcriptase inhibitors (Q34058254) (← links)
• The M184V mutation reduces the selective excision of zidovudine 5'-monophosphate (AZTMP) by the reverse transcriptase of human immunodeficiency virus type 1 (Q34334682) (← links)
• Virulence and reduced fitness of simian immunodeficiency virus with the M184V mutation in reverse transcriptase (Q34339657) (← links)
• Robust growth of human immunodeficiency virus type 1 (HIV-1) (Q34351276) (← links)
• The M184V mutation in reverse transcriptase can delay reversion of attenuated variants of simian immunodeficiency virus. (Q34361509) (← links)
• Virus population dynamics, fitness variations and the control of viral disease: an update (Q34452529) (← links)
• Reversion of the M184V mutation in simian immunodeficiency virus reverse transcriptase is selected by tenofovir, even in the presence of lamivudine. (Q34465037) (← links)
• An RNAi in silico approach to find an optimal shRNA cocktail against HIV-1. (Q34499103) (← links)
• A Leu to Ile but not Leu to Val change at HIV-1 reverse transcriptase codon 74 in the background of K65R mutation leads to an increased processivity of K65R+L74I enzyme and a replication competent virus (Q34573897) (← links)
• Select resistance-associated mutations in blood are associated with lower CSF viral loads and better neuropsychological performance (Q34615228) (← links)